Amphastar Pharma Q3 Adj EPS $1.15 Beats $0.69 Estimate, Sales $180.56M Beat $174.63M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amphastar Pharma reported Q3 adjusted earnings of $1.15 per share, beating the analyst consensus estimate of $0.69 by 66.67%. This is a 202.63% increase from the same period last year. The company also reported quarterly sales of $180.56 million, beating the analyst consensus estimate of $174.63 million by 3.39%. This is a 50.30% increase from the same period last year.
November 08, 2023 | 9:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amphastar Pharma's Q3 earnings and sales exceeded estimates, indicating strong financial performance.
Amphastar Pharma's Q3 earnings and sales exceeded analyst estimates, which is a positive signal for the company's financial performance. This could lead to an increase in the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100